Table 2 Association between patient, tumor features and response to radiotherapy, 3Â months after completion
From: Biomarkers of resistance to radiation therapy: a prospective study in cervical carcinoma
Features | Responders | non-responders | Value - p |
|---|---|---|---|
(n = 92) | (n = 35) | ||
Median Age, years (SD) | 47.5 (11.9) | 49.9 (12.6) | 0.17 |
Median Tumor size, cm (SD) | 6.4 (2.0) | 6.7 (2.1) | 0.58 |
FIGO staging, number of patients (%) | Â | Â | 0.26* |
   IIB | 36 (78.3) | 10 (21.7) |  |
   IIIB | 56 (69.1) | 25 (30.9) |  |
Differentiation degree, number of patients (%) | |||
   Well | 7 (77.8) | 2 (22.2) | 0.62* |
   Moderetaly | 65 (75.6) | 21 (24.4) |  |
   Poorly | 11 (64.7) | 6 (35.3) |  |
Treatment type, number of patients (%) | Â | Â | 0.21* |
Exclusive EBRT + Brachytherapy | 36 (66.7) | 18 (33.3) | Â |
Chemo-Radiotherapy + Brachytherapy | 56 (76.7) | 17 (23.3) | Â |
Protein Expression, number of patients (%) | |||
CAIX | Â | Â | Â |
  Negative | 63 (70) | 27 (30) | 0.02**₤ |
  Positive | 19(95) | 1 (5) |  |
HIF1 α | |||
  Negative | 27 (81.8) | 6 (18.2) | 0.14*₤ |
  Positive | 63 (68.4) | 29 (31.6) |  |
GLUT1 | |||
  Negative | 52 (72.2) | 20 (27.8) | 0.44*₤ |
  Positive | 30 (78.9) | 8 (21.1) |  |
IGF1R α | |||
  Negative | 17 (65.3) | 9 (34.7) | 0.39*₤ |
  Positive | 73 (73.7) | 26 (26.3) |  |
IGF1R β | |||
  Negative | 22 (75.8) | 7 (24.2) | 0.59*₤ |
  Positive | 68 (70.9) | 28 (29.1) |  |
Survivin | |||
  Negative | 11 (78.6) | 3 (21.4) | 0.67*₤ |
  Positive | 74 (73.3) | 27 (26.7) |  |
Impact of anemia, number of patients (%) | |||
  Hb > 11 g/dl | 71 (78) | 20 (21.9) | 0.02* |
  Hb ≤ 11 g/dl | 21 (58.3) | 15 (41.6) |  |